Joint Symposium 5
Drug Development + Radiopharmacy + Oncology & Theraonotics Committee / Society of Radiopharmaceutical Sciences (SRS)
Accessible on-demand at any time

Session Title
Targeting Cancer with Peptides, Fragments or Antibodies

Chairperson
Yann Seimbille (Rotterdam, Netherlands)

Programme
29 min Simone Dalm (Rotterdam, Netherlands): In Peptides, We Trust!

29 min Nick Devoogdt (Brussels, Belgium): Antibody Fragments, Fast Kinetics are Essential!

29 min Brian M. Zeglis (New York, United States of America / SRS): Antibodies as Radiopharmaceutical Vectors - Do the Benefits Outweigh the Costs?

3 min Session Summary by Chairperson

Educational Objectives
1. Improve understanding of the current challenges associated with the design of cancer targeting radiopharmaceuticals.
2. Critical appraisal of the different class of radiopharmaceuticals based on biovectors for cancer imaging and therapy.
3. Discuss benefits and obstacles associated with their theranostic applications.

Summary
Cancer is indisputably one of the main challenges in healthcare and Nuclear Medicine is nowadays playing an essential role in the diagnosis and treatment of tumors. Many antineoplastic theranostic agents based on peptides, antibodies and antibody fragments have emerged over the last decade. However, each of these biovectors presents advantages and limitations. For instance, peptides are known to offer high versatility, antibodies specificity and antibody fragments fast kinetics. Therefore, which class of biovectors is the most suitable to develop tumor targeting radiopharmaceuticals? This session aims to discuss the benefits and challenges encountered for each category of radiopharmaceuticals, the future developments and their applications as theranostics.

Key Words
Cancer, Theranostics, Radiopharmaceuticals, Peptides, Antibodies, Antibody fragments